Indonesia Revises KBLI Classification Structure Affecting Regulated Wholesale Activities

On 18 December 2025, Indonesia’s Central Statistics Agency (BPS) issued “BPS Regulation No. 7 of 2025 on the Indonesian Standard Industrial Classification (KBLI).” The regulation updates Indonesia’s official business classification framework through targeted renumbering and consolidation of KBLI codes, with direct consequences for company licensing, OSS records, and sectoral regulatory compliance.

Role of KBLI in Indonesia’s Licensing and Compliance Framework

KBLI (Klasifikasi Baku Lapangan Usaha Indonesia) is Indonesia’s authoritative system for defining and classifying business activities. Each registered KBLI code determines the legally recognized scope of a company’s operations and serves as a reference point for regulatory oversight.

KBLI codes are embedded in:

Business Identification Number (NIB) records
The Online Single Submission (OSS) licensing system
Sectoral permits and operational approvals
Ongoing regulatory reporting and compliance filings

Because KBLI codes define the legally recognized scope of a company’s activities, any update may affect existing licenses, permitted operations, and eligibility for regulated activities.

Key Structural Changes Introduced by BPS Regulation No. 7 of 2025

BPS Regulation No. 7 of 2025 introduces targeted revisions to KBLI codes, with a particular focus on wholesale trade activities in regulated health-related sectors. The revisions consist of both administrative renumbering and substantive consolidation of previously segmented classifications.

Renumbered KBLI Codes Affecting Regulated Wholesale Activities

The following wholesale trade classifications have been renumbered without substantive scope changes:

KBLI 46691 → KBLI 46791
Wholesale Trade of Medical Devices and Laboratory Equipment for Human Use
KBLI 46643 → KBLI 46743
Wholesale Trade of Radioactive Substances and Ionizing Radiation Generators

Companies operating under these categories must update their business data to reflect the new numbering.

Consolidation of Pharmaceutical, Cosmetic, and Raw Material Activities

More substantive changes have been introduced for wholesale activities related to pharmaceuticals, cosmetics, traditional medicines, and raw materials. Under the previous KBLI structure, these activities were divided across multiple narrowly defined codes, separated by product type, end use, and stage of production.

Under “BPS Regulation No. 7 of 2025,” these activities have been consolidated into two principal classifications:

KBLI 46441 – Wholesale Trade of Pharmaceutical Preparations for Human Use
KBLI 46442 – Wholesale Trade of Pharmaceutical Preparations for Animal Use

The revised KBLI 46441 and KBLI 46442 collectively cover wholesale trade of medicinal products, cosmetics such as perfume and soap, pharmaceutical raw materials, and other pharmaceutical preparations. Companies previously registered under multiple legacy KBLI codes must now align their activities under the appropriate consolidated classification based on the intended end use of the products handled.

Transition Period and Next Steps for Companies

BPS Regulation No. 7 of 2025 establishes a six-month transition period for companies to update their KBLI classifications, with a compliance deadline set at June 18, 2026. During this transition period, businesses are expected to ensure that their registered business activities accurately reflect the new KBLI structure across all regulatory platforms.

Companies operating in affected sectors should conduct a structured review of their registered business data. This includes confirming whether existing KBLI codes have been renumbered or consolidated and submitting the necessary updates to OSS and related licensing records. Ensuring consistency across all regulatory submissions is critical to avoid administrative discrepancies.

Failure to complete KBLI updates within the prescribed transition period may result in inconsistencies in OSS licensing data, delays in permit amendments or renewals, and potential complications during regulatory inspections or audits.

Final Thoughts

Although the changes introduced by BPS Regulation No. 7 of 2025 are largely structural, they carry tangible compliance implications for companies active in Indonesia’s regulated health sectors. Timely alignment with the revised KBLI framework is essential to maintain license continuity and regulatory certainty. For international manufacturers, importers, and distributors active in Indonesia’s regulated health sectors, early alignment with the updated KBLI framework is critical.

For support in assessing KBLI impact, updating OSS records, and maintaining regulatory consistency across Indonesia’s evolving compliance landscape, get in touch with Cisema today.